Empirical_JJ bayes_NNS screening_VBG for_IN multi-item_JJ associations_NNS
This_DT paper_NN considers_VBZ the_DT framework_NN of_IN the_DT so-called_JJ ``_`` market_NN basket_NN problem_NN ''_'' ,_, in_IN which_WDT a_DT database_NN of_IN transactions_NNS is_VBZ mined_VBN for_IN the_DT occurrence_NN of_IN unusually_RB frequent_JJ item_NN sets_NNS ._.
In_IN our_PRP$ case_NN ,_, ``_`` unusually_RB frequent_JJ ''_'' involves_VBZ estimates_NNS of_IN the_DT frequency_NN of_IN each_DT item_NN set_NN divided_VBN by_IN a_DT baseline_NN frequency_NN computed_VBN as_IN if_IN items_NNS occurred_VBD independently_RB ._.
The_DT focus_NN is_VBZ on_IN obtaining_VBG reliable_JJ estimates_NNS of_IN this_DT measure_NN of_IN interestingness_NN for_IN all_DT item_NN sets_NNS ,_, even_RB item_NN sets_NNS with_IN relatively_RB low_JJ frequencies_NNS ._.
For_IN example_NN ,_, in_IN a_DT medical_JJ database_NN of_IN patient_NN histories_NNS ,_, unusual_JJ item_NN sets_NNS including_VBG the_DT item_NN ``_`` patient_NN death_NN ''_'' -LRB-_-LRB- or_CC other_JJ serious_JJ adverse_JJ event_NN -RRB-_-RRB- might_MD hopefully_RB be_VB flagged_VBN with_IN as_RB few_JJ as_IN 5_CD or_CC 10_CD occurrences_NNS of_IN the_DT item_NN set_NN ,_, it_PRP being_VBG unacceptable_JJ to_TO require_VB that_DT item_NN sets_NNS occur_VBP in_IN as_RB many_JJ as_IN 0.1_CD %_NN of_IN millions_NNS of_IN patient_NN reports_NNS before_IN the_DT data_NNS mining_NN algorithm_NN detects_VBZ a_DT signal_NN ._.
Similar_JJ considerations_NNS apply_VBP in_IN fraud_NN detection_NN applications_NNS ._.
Thus_RB we_PRP abandon_VBP the_DT requirement_NN that_IN interesting_JJ item_NN sets_NNS must_MD contain_VB a_DT relatively_RB large_JJ fixed_JJ minimal_JJ support_NN ,_, and_CC adopt_VB a_DT criterion_NN based_VBN on_IN the_DT results_NNS of_IN fitting_JJ an_DT empirical_JJ Bayes_NNP model_NN to_TO the_DT item_NN set_NN counts_NNS ._.
The_DT model_NN allows_VBZ us_PRP to_TO define_VB a_DT 95_CD %_NN Bayesian_JJ lower_JJR confidence_NN limit_NN for_IN the_DT ``_`` interestingness_NN ''_'' measure_NN of_IN every_DT item_NN set_NN ,_, whereupon_NN the_DT item_NN sets_NNS can_MD be_VB ranked_VBN according_VBG to_TO their_PRP$ empirical_JJ Bayes_NNP confidence_NN limits_NNS ._.
For_IN item_NN sets_NNS of_IN size_NN J_NN -RRB-_-RRB- 2_CD ,_, we_PRP also_RB distinguish_VBP between_IN multi-item_JJ associations_NNS that_WDT can_MD be_VB explained_VBN by_IN the_DT observed_VBN J_NN -LRB-_-LRB- J-1_NN -RRB-_-RRB- \/_: 2_CD pairwise_JJ associations_NNS ,_, and_CC item_NN sets_NNS that_WDT are_VBP significantly_RB more_RBR frequent_JJ than_IN their_PRP$ pairwise_JJ associations_NNS would_MD suggest_VB ._.
Such_JJ item_NN sets_NNS can_MD uncover_VB complex_JJ or_CC synergistic_JJ mechanisms_NNS generating_VBG multi-item_JJ associations_NNS ._.
This_DT methodology_NN has_VBZ been_VBN applied_VBN within_IN the_DT U.S._NNP Food_NNP and_CC Drug_NNP Administration_NNP -LRB-_-LRB- FDA_NNP -RRB-_-RRB- to_TO databases_NNS of_IN adverse_JJ drug_NN reaction_NN reports_NNS and_CC within_IN AT&T_NNP to_TO customer_NN international_JJ calling_NN histories_NNS ._.
We_PRP also_RB present_VBP graphical_JJ techniques_NNS for_IN exploring_VBG and_CC understanding_VBG the_DT modeling_NN results_NNS ._.
